Mixed views on Broad’s fate after EPO revokes CRISPR patent

Press/Media: Press / Media

18/01/2018

Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office (EPO) to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.

In that context I was interviewed by the Life Science Intellectual Property Review

References

  • Mixed views on Broad’s fate after EPO revokes CRISPR patent

    Newton Media Ltd, United Kingdom

    Life Science Intellectual Property Review

    Research areas

  • Gene editing, CRISPR, Broad Institute, Patents, EPO, CRISPR, EPO, European Patent Office, patent revocation, Broad Institute, Allen & Overy, ERS Genomics, Timo Minssen

ID: 188522799